

PRESS RELEASE

Gilbert Technologies names Scott Fleming Chief Commercial Officer

EINDHOVEN, the Netherlands, February 21, 2022

Organizational update 2022

Gilbert Technologies B.V., an early stage Netherlands based MedTech Company utilizing proprietary electro hydrodynamic atomization (EHDA) platform technology to create a next generation soft mist inhalation device, today announced Scott Fleming has been named Chief Commercial Officer. Mr. Fleming previously held the position of Technology Director.

“For the last three years, we have worked closely with Scott on the development of our technology making substantial progress on the development of our first prototype, and preparing the foundation for the development of our clinical device,” said Maurits Huigen, Chief Executive Officer of Gilbert Technologies. “We are privileged to name him Chief Commercial Officer as we continue our progress towards our mission to redefine treatment for lung patients with difficult to treat conditions. Scott’s broad experience will play a pivotal role in getting to key inflection points on the development of our clinical device and our partnerships with pharmaceutical companies.”

“I am excited to continue my journey with the Gilbert team as CCO. I have been very impressed by the potential the electrospray technology offers to deliver more advanced pulmonary drugs (large- and small molecules) in a targeted way to patients by inhalation, making treatments safer and more effective”, said Scott Fleming. “Chronic lung diseases remain the third leading cause of death and disability worldwide. This drives me to deliver on the promise of our mission to make medical treatment easier and more effective, to save lives and help patients live the life they want, while reducing the burden on our healthcare systems.”

Mr. Fleming ([Scott Fleming | LinkedIn](#)), a US citizen and Netherlands resident, joined Gilbert in 2019 serving as Technology Director. He brings nearly 30 years’ experience in the pharmaceutical, drug delivery and digital health industries, with a background that includes management & technology consulting, entrepreneurship and executive commercial positions in both large and specialty pharmaceutical companies. Before joining Gilbert he co-founded MicroDose Therapeutx, a drug delivery and specialty pharmaceutical company which was acquired by Teva Pharmaceuticals in 2013. At Teva he served as Global Brand Lead for eConnectivity of respiratory devices and at Adherium Europe as sr. Vice President, he has been active in digital healthcare with smart inhalers.

Not for publication: For more information, please contact:

Gilbert Technologies B.V., High Tech Campus 27, P148, 5656 AE Eindhoven the Netherlands.
Maurits Huigen, Chief Executive Officer. E-mail: huigen@gilberttechnologies.eu. Tel: +31 62 790 9880.
Website: www.gilberttechnologies.eu.

* EHDA = Electro Hydro Dynamic Atomization